Von Willebrand Factor Ristocetin Co-factor Activity to Von Willebrand Factor Antigen Level Ratio for Diagnosis of Acquired Von Willebrand Syndrome Caused by Aortic Stenosis

Background: Severe aortic stenosis (AS) causes acquired von Willebrand syndrome by the excessive shear stress-dependent cleavage of high molecular weight multimers of von Willebrand factor (VWF). While the current standard diagnostic method is so-called VWF multimer analysis that is western blotting under nonreducing conditions, it remains unclear whether a ratio of VWF Ristocetin co-factor activity (VWF:RCo) to VWF antigen levels (VWF:Ag) of <0.7, which can be measured with an automated coagulation analyzer in clinical laboratories and is used for the diagnosis of hereditary von Willebrand disease.

Objectives: To evaluated whether the VWF:RCo/VWF:Ag is useful for the diagnosis of AS-induced acquired von Willebrand syndrome.

Methods: VWF:RCo and VWF:Ag were evaluated with the VWF large multimer index as a reference, which represents the percentage of a patient's VWF high molecular weight multimer ratio to that of standard plasma in the VWF multimer analysis.

Results: We analyzed 382 patients with AS having transaortic valve maximal pressure gradients of >30 mmHg, 27 patients with peripheral artery disease, and 46 control patients free of cardiovascular disease with osteoarthritis, diabetes, and so on. We assumed a large multimer index of <80% as loss of VWF large multimers since 59.0% of patients with severe AS had the indices of <80%, while no control patients or patients with peripheral artery disease, except for 2 patients, exhibited the indices of <80%. The VWF:RCo/VWF:Ag ratios, measured using an automated blood coagulation analyzer, were correlated with the indices (r = 0.470, < .001). When the ratio of <0.7 was used as a cut-off point, the sensitivity and specificity to VWF large multimer indices of <80% were 0.437 and 0.826, respectively.

Conclusion: VWF:RCo/VWF:Ag ratios of <0.7 may indicate loss of VWF large multimers with high specificity, but low sensitivity. VWF:RCo/VWF:Ag ratios in patients with AS having a ratio of <0.7 may be useful for monitoring the loss of VWF large multimers during their clinical courses.

Citing Articles

Bleeding in valvular heart disease: is von Willebrand factor the culprit?.

Bakhtari S, Vincent F, Susen S Res Pract Thromb Haemost. 2024; 8(5):102506.

PMID: 39156182 PMC: 11328092. DOI: 10.1016/j.rpth.2024.102506.

Mitral regurgitation is associated with similar loss of von Willebrand factor large multimers but lower frequency of anemia compared with aortic stenosis.

Takiguchi H, Miura M, Shirai S, Soga Y, Hanyu M, Sakaguchi G Res Pract Thromb Haemost. 2024; 8(4):102431.

PMID: 38840664 PMC: 11152679. DOI: 10.1016/j.rpth.2024.102431.

Impact of extracorporeal membrane oxygenation treatments on acquired von Willebrand syndrome in patients with out-of-hospital cardiac arrest: a retrospective observational study.

Chiba Y, Goto K, Suzuki M, Horiuchi H, Hayakawa M Thromb J. 2024; 22(1):46.

PMID: 38822325 PMC: 11143620. DOI: 10.1186/s12959-024-00617-4.

References

Pipe S, Montgomery R, Pratt K, Lenting P, Lillicrap D . Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016; 128(16):2007-2016. PMC: 5073181. DOI: 10.1182/blood-2016-04-713289. View

Sadler J . Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67:395-424. DOI: 10.1146/annurev.biochem.67.1.395. View

Franchini M . Hemostasis and aging. Crit Rev Oncol Hematol. 2006; 60(2):144-51. DOI: 10.1016/j.critrevonc.2006.06.004. View

Wise R, Dorner A, Krane M, Pittman D, Kaufman R . The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem. 1991; 266(32):21948-55. View

Vlot A, Koppelman S, van den Berg M, Bouma B, Sixma J . The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood. 1995; 85(11):3150-7. View

Vangenechten I, Mayger K, Smejkal P, Zapletal O, Michiels J, Moore G . A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients. J Thromb Haemost. 2018; 16(7):1268-1277. DOI: 10.1111/jth.14145. View

Tiede A . Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res. 2013; 130 Suppl 2:S2-6. DOI: 10.1016/S0049-3848(13)70003-3. View

Randi A, Laffan M, Starke R . Von Willebrand factor, angiodysplasia and angiogenesis. Mediterr J Hematol Infect Dis. 2013; 5(1):e2013060. PMC: 3787682. DOI: 10.4084/MJHID.2013.060. View

Konkle B . Von Willebrand factor and aging. Semin Thromb Hemost. 2014; 40(6):640-4. DOI: 10.1055/s-0034-1389079. View

10.

Sadler J, Budde U, Eikenboom J, Favaloro E, Hill F, Holmberg L . Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4(10):2103-14. DOI: 10.1111/j.1538-7836.2006.02146.x. View

11.

Koppelman S, van Hoeij M, Vink T, Lankhof H, Schiphorst M, Damas C . Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood. 1996; 87(6):2292-300. View

12.

Fischer B, Kramer G, Mitterer A, Grillberger L, Reiter M, Mundt W . Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res. 1996; 84(1):55-66. DOI: 10.1016/0049-3848(96)00161-2. View

13.

Federici A, Budde U, Castaman G, Rand J, Tiede A . Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013; 39(2):191-201. DOI: 10.1055/s-0033-1334867. View

14.

Sakatsume K, Saito K, Akiyama M, Sasaki K, Kawatsu S, Takahashi G . Association between the severity of acquired von Willebrand syndrome and gastrointestinal bleeding after continuous-flow left ventricular assist device implantation. Eur J Cardiothorac Surg. 2018; 54(5):841-846. DOI: 10.1093/ejcts/ezy172. View

15.

Eura Y, Kokame K . Commonly used anti-von Willebrand factor antibody for multimer analysis cross-reacts with fibronectin, which is difficult to distinguish from von Willebrand factor. Res Pract Thromb Haemost. 2021; 5(6):e12598. PMC: 8449288. DOI: 10.1002/rth2.12598. View

16.

De Jong A, Dirven R, Oud J, Tio D, van Vlijmen B, Eikenboom J . Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor. J Thromb Haemost. 2018; 16(7):1357-1368. DOI: 10.1111/jth.14140. View

17.

Peyvandi F, Garagiola I, Baronciani L . Role of von Willebrand factor in the haemostasis. Blood Transfus. 2011; 9 Suppl 2:s3-8. PMC: 3159913. DOI: 10.2450/2011.002S. View

18.

Budde U, Pieconka A, Will K, Schneppenheim R . Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost. 2006; 32(5):514-21. DOI: 10.1055/s-2006-947866. View

19.

Tamura T, Horiuchi H, Imai M, Tada T, Shiomi H, Kuroda M . Unexpectedly High Prevalence of Acquired von Willebrand Syndrome in Patients with Severe Aortic Stenosis as Evaluated with a Novel Large Multimer Index. J Atheroscler Thromb. 2015; 22(11):1115-23. DOI: 10.5551/jat.30809. View

20.

Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F . Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003; 349(4):343-9. DOI: 10.1056/NEJMoa022831. View